Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Summary

Atossa Therapeutics announced a Contingent Value Rights agreement where shareholders will receive one CVR per share, entitling holders to 25% of net proceeds from monetization of the company's first qualifying priority review voucher, capped at $50 million in aggregate.